CN106667973A - 一种用于防雾霾损伤的组合物及其制备方法和喷剂 - Google Patents
一种用于防雾霾损伤的组合物及其制备方法和喷剂 Download PDFInfo
- Publication number
- CN106667973A CN106667973A CN201710054164.6A CN201710054164A CN106667973A CN 106667973 A CN106667973 A CN 106667973A CN 201710054164 A CN201710054164 A CN 201710054164A CN 106667973 A CN106667973 A CN 106667973A
- Authority
- CN
- China
- Prior art keywords
- compositionss
- composition
- acid
- preparation
- haze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007921 spray Substances 0.000 title claims abstract description 19
- 230000006378 damage Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 title abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims abstract description 12
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 12
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 12
- 229930002875 chlorophyll Natural products 0.000 claims abstract description 12
- 235000019804 chlorophyll Nutrition 0.000 claims abstract description 12
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims abstract description 12
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims abstract description 12
- 229940114124 ferulic acid Drugs 0.000 claims abstract description 12
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000001785 ferulic acid Nutrition 0.000 claims abstract description 12
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 12
- 229940016667 resveratrol Drugs 0.000 claims abstract description 12
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 11
- 241001061264 Astragalus Species 0.000 claims abstract description 9
- 235000006533 astragalus Nutrition 0.000 claims abstract description 9
- 210000004233 talus Anatomy 0.000 claims abstract description 9
- SNKFFCBZYFGCQN-VWUOOIFGSA-N salvianolic acid B Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims description 20
- 238000000889 atomisation Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 229930014669 anthocyanidin Natural products 0.000 claims description 11
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims description 11
- 235000008758 anthocyanidins Nutrition 0.000 claims description 11
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 10
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 5
- 150000004676 glycans Chemical class 0.000 abstract description 3
- 239000005017 polysaccharide Substances 0.000 abstract description 3
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 abstract 1
- 235000010208 anthocyanin Nutrition 0.000 abstract 1
- 229930002877 anthocyanin Natural products 0.000 abstract 1
- 239000004410 anthocyanin Substances 0.000 abstract 1
- 150000004636 anthocyanins Chemical class 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000003570 air Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003915 air pollution Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 238000003912 environmental pollution Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- HZEBHPIOVYHPMT-OUBTZVSYSA-N Polonium-210 Chemical compound [210Po] HZEBHPIOVYHPMT-OUBTZVSYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 210000004903 cardiac system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- ZGFPIGGZMWGPPW-UHFFFAOYSA-N formaldehyde;formic acid Chemical compound O=C.OC=O ZGFPIGGZMWGPPW-UHFFFAOYSA-N 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229910052704 radon Inorganic materials 0.000 description 1
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960002415 trichloroethylene Drugs 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种用于防雾霾损伤的组合物,包含0.0788‑0.1182mg/ml的阿魏酸、0.08‑0.12mg/ml的白藜芦醇、0.075‑0.125mg/ml黄芪多糖、0.078‑0.12mg/ml的丹参酸B、0.00008‑0.00012mg/ml的无水乙醇、0.15‑0.25mg/ml的花青素,0.2‑0.3mg/ml的叶绿素,还涉及一种用于防雾霾损伤的组合物,其制备方法,以及用所述组合物制备的雾化喷剂。通过使用所述组合物和雾化喷剂,可有效防止雾霾对肺组织的损伤,并对已损伤组织进行修复。
Description
技术领域
本发明涉及卫生保健领域,更特别地,涉及一种用于防雾霾损伤的组合物,其制备方法,以及用所述组合物制备的雾化喷剂。
背景技术
随着时代的发展,人们越来越关注空气质量对生活的影响。雾霾是一种大气污染状态,是对大气中各种悬浮颗粒物含量超标的笼统表述,二氧化硫、氮氧化物以及可吸入颗粒物是雾霾主要组成成分。一般而言,雾和霾是在具体成分上存在一定不同。雾中含有各种对人体有害的细颗粒、有毒物质达20多种,包括了酸、碱、盐、胺、酚等,以及尘埃、花粉、螨虫、流感病毒、结核杆菌、肺炎球菌等,其含量是普通大气水滴的几十倍。与雾相比,霾对人的身体健康的危害更大。其中有害健康的主要是直径小于10微米的气溶胶粒子,如矿物颗粒物、海盐、硫酸盐、硝酸盐、有机气溶胶粒子、燃料和汽车废气等,它能直接进入并粘附在人体呼吸道和肺泡中。尤其是亚微米粒子会分别沉积于上、下呼吸道和肺泡中,引起急性鼻炎和急性支气管炎等病症。对于支气管哮喘、慢性支气管炎、阻塞性肺气肿和慢性阻塞性肺疾病等慢性呼吸系统疾病患者,雾霾可使病情急性发作或急性加重。如果长期处于这种环境还有可能诱发肺癌。
雾霾对人体心脑血管疾病的影响也很严重,会阻碍正常的血液循环,导致心血管病、高血压、冠心病、脑溢血,可能诱发心绞痛、心肌梗塞、心力衰竭等,使慢性支气管炎出现肺源性心脏病等。
有足够的科学研究结果证明,大气细粒子能吸附大量有致癌物质和基因毒性诱变物质,给人体健康带来不可忽视的负面影响,包括提高死亡率、使慢性病加剧、使呼吸系统及心脏系统疾病恶化,改变肺功能及结构、影响生殖能力、改变人体的免疫结构等。
室内污染主要是由于室内空气中存在的多种挥发性有机物而对室内环境造成污染的现象。室内空气污染物的主要来源有以下几个方面:建筑及室内装饰材料、室外污染物、燃烧产物、吸烟、室外雾霾天气影响和人本身活动。其中室内装饰材料及家具的污染是目前造成室内空气污染的主要方面。此外,吸烟包括二手烟也是危害广泛的引起室内空气污染的重要原因。有研究指出,即便是二手烟,仍然含有焦油、阿摩尼亚、尼古丁、悬浮微粒、PM2.5、钋-210等超过4000种有害化学物质及数十种致癌物质。
室内空气污染危害较大的主要有氡、甲醛、苯、氨以及酯、三氯乙烯等。美国专家检测发现,在室内空气中存在500多种挥发性有机物,其中致癌物质有20多种,致病病毒200多种。大量触目惊心的事实证实,室内空气污染已成为危害人类健康的“隐形杀手”,也是全世界各国共同关注的问题。世界卫生组织也将室内空气污染与高血压、胆固醇过高症以及肥胖症等共同列为人类健康的10大威胁。据统计,全球近一半的人处于室内空气污染中,室内环境污染已经引起35.7%的呼吸道疾病,22%的慢性肺病和15%的气管炎、支气管炎和肺癌。
上述环境污染带来的有害物质(主要是超氧化物质)经呼吸道吸入肺部,可以在肺部形成炎性反应,并进而造成组织细胞的损害,长期积累引发细胞突变而发生肿瘤(如肺癌),细胞死亡而发生纤维细胞增生造成肺纤维化甚至肺硬化。危害物质经肺入血会造成血管损伤,并进而形成血栓造成血栓病。
因此,需要一种药物喷剂用于预防或治疗雾霾或室内有害物质造成的一些病症或症状。
发明内容
为解决以上问题,本发明提供了一种用于防雾霾损伤的组合物,包含0.0788-0.1182mg/ml的阿魏酸、0.08-0.12mg/ml的白藜芦醇、0.075-0.125mg/ml黄芪多糖、0.078-0.12mg/ml的丹参酸B、0.00008-0.00012mg/ml的无水乙醇、0.15-0.25mg/ml的花青素,0.2-0.3mg/ml的叶绿素。
优选地,所述组合物的溶剂为水或生理盐水。
本发明还公开了上述组合物的制备方法,包括以下步骤:
S1:将阿魏酸、白藜芦醇、黄芪多糖、丹参酸B、无水乙醇、花青素、叶绿素按相应的量加入溶剂中,加热搅拌至完全溶解;
S2:定容,即得到所述组合物。
优选地,所述溶剂为水或生理盐水。
所述组合物可通过加湿器雾化以改良环境空气质量并具有抗雾霾及室内环境污染造成的损伤作用,雾化后天然提取物可直接从口腔,气道达肺泡,缓解肺部因环境污染造成的损伤,除了室内加湿器外,还可通过个人吸入雾化器,车载雾化加湿器等方式使用。
本发明还公开了上述组合物的另一种制备方法,包括以下步骤:
S1’:将阿魏酸、白藜芦醇、黄芪多糖、丹参酸B、无水乙醇、花青素、叶绿素按相应的量的5-10倍加入溶剂中,加热搅拌至完全溶解;
S2’:定容制备成高浓度储存液;
S3’:使用前取所述高浓度储存液稀释成相应浓度,即得到所述组合物。
本发明还公开了一种用于防雾霾损伤的雾化喷剂,其由上述组合物制成。
所用物质的有益效果为:
1、阿魏酸:抗血小板凝集和血栓;抗炎;清除氧自由基、亚硝酸盐、过氧化亚硝基;增强免疫功能;抗菌、抗病毒;抗肿瘤;抗突变等。
2、白藜芦醇:抗衰老、抗肿瘤、防治心脑血管疾病、抗菌、抗氧化、免疫调节抗喘等生物活性。
3、黄芪多糖:具有增强免疫系统功能、抗肿瘤、保肝、降血糖、抗病毒、抗氧化延缓衰老等作用。
4、丹参酸:祛瘀止痛、活血通经、清心除烦之功效与抗心肌缺血、抗脑缺血、抗血栓、改善微循环、促进组织的修复与再生,以及镇静镇痛等多种药理作用。
5、乙醇:乙醇和甲醇竞争醇脱氢酶,甲醇和乙醇进入体内之后,在醇脱氢酶作用下变成甲醛、乙醛,甲醛和乙醛在醛脱氢酶作用下变成甲酸和乙酸。乙酸会被细胞内的氧化酶体系进一步代谢分解,最终变成二氧化碳和水,并为人体提供能量。而甲酸就不能继续被代谢,会蓄积起来,造成中毒。加入乙醇可抑制甲醇的氧化,减少甲醛甲酸的产生量。
6、花青素:强效抗氧化剂,是羟基供体,同时也是一种自由基清除剂,它能和蛋白质结合防止过氧化。可维持正常的细胞连结、血管的稳定、增进微细血管循环、提高微血管和静脉的流动。
7、叶绿素:杀菌消炎、富含铁元素,可造血、提供维生素、解毒、解除体内药物残渣、预防癌症,维持酶的活性,使其发挥出极强的抗氧化作用,抵抗自由基,延缓衰老。抑制代谢过程中产生的硫化物。
通过使用以上组合物或喷剂,可有效防止雾霾对肺组织及血管的损伤,并对已损伤组织进行修复。
具体实施方式
以下结合实例对本发明的原理和特征进行描述,所举实例只用于解释本发明,并非用于限定本发明的范围。
实施例1
取浓度98.5%的阿魏酸0.08g,浓度10%的水溶性白藜芦醇0.8g,浓度50%的黄芪多糖0.15g,60%丹参酸B 0.13g,99%无水乙醇0.08ml,花青素0.15g,叶绿素0.20g,加入纯水,加热搅拌至完全溶解,定容至1000ml,制备成低浓度的雾化喷剂。
将配制好的雾化喷剂加入加湿器水箱中,打开开关调至中速加湿雾化,约2-4小时可使用完毕,时间长短因加湿器品牌型号不同而略有差异。
实施例2
取浓度98.5%的阿魏酸0.1g,浓度10%的水溶性白藜芦醇1g,浓度50%的黄芪多糖0.2g,60%丹参酸B0.17g,99%无水乙醇0.1ml,花青素0.2g,叶绿素0.25g,加入纯水,加热搅拌至完全溶解,定容至1000ml,制备成低浓度的雾化喷剂。
将配制好的雾化喷剂加入加湿器水箱中,打开开关调至中速加湿雾化,约2-4小时可使用完毕,时间长短因加湿器品牌型号不同而略有差异。
实施例3
取浓度98.5%的阿魏酸0.12g,浓度10%的水溶性白藜芦醇1.2g,浓度50%的黄芪多糖0.25g,60%丹参酸B 0.2g,99%无水乙醇0.12ml,花青素0.25g,叶绿素0.3g,加入纯水,加热搅拌至完全溶解,定容至1000ml,制备成低浓度的雾化喷剂。
将配制好的雾化喷剂加入加湿器水箱中,打开开关调至中速加湿雾化,约2-4小时可使用完毕,时间长短因加湿器品牌型号不同而略有差异。
实施例4
取浓度98.5%的阿魏酸1g,浓度10%的水溶性白藜芦醇10g,浓度50%的黄芪多糖2g,60%丹参酸B1.7g,99%无水乙醇1ml,花青素2g,叶绿素2.5g,加入纯水,加热搅拌至完全溶解,定容至1000ml,制备成高浓度的雾化喷剂。高浓度雾化喷剂可稀释使用,方便储存。
将配制好的高浓度雾化喷剂100ml,加入加湿器水箱中,再加入900ml纯水,混匀,打开开关调至中速加湿雾化,约2-4小时可使用完毕,时间长短因加湿器品牌型号不同而略有差异。
通过使用以上实施例中的喷剂,可有效防止雾霾对肺组织及血管的损伤,并对已损伤组织进行修复。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (6)
1.一种用于防雾霾损伤的组合物,其特征在于,包含0.0788-0.1182mg/ml的阿魏酸、0.08-0.12mg/ml的白藜芦醇、0.075-0.125mg/ml黄芪多糖、0.078-0.12mg/ml的丹参酸B、0.00008-0.00012mg/ml的无水乙醇、0.15-0.25mg/ml的花青素,0.2-0.3mg/ml的叶绿素。
2.根据权利要求1所述的组合物,其特征在于,所述组合物的溶剂为水或生理盐水。
3.一种如权利要求1或2所述的组合物的制备方法,其特征在于,包括以下步骤:
S1:将阿魏酸、白藜芦醇、黄芪多糖、丹参酸B、无水乙醇、花青素、叶绿素按相应的量加入溶剂中,加热搅拌至完全溶解;
S2:定容,即得到所述组合物。
4.根据权利要求3所述的制备方法,其特征在于,所述溶剂为水或生理盐水。
5.一种如权利要求1或2所述的组合物的制备方法,其特征在于,包括以下步骤:
S1’:将阿魏酸、白藜芦醇、黄芪多糖、丹参酸B、无水乙醇、花青素、叶绿素按相应的量的5-10倍加入溶剂中,加热搅拌至完全溶解;
S2’:定容制备成高浓度储存液;
S3’:使用前取所述高浓度储存液稀释成相应浓度,即得到所述组合物。
6.一种用于防雾霾损伤的雾化喷剂,其特征在于,由权利要求1或2所述的组合物制成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710054164.6A CN106667973A (zh) | 2017-01-22 | 2017-01-22 | 一种用于防雾霾损伤的组合物及其制备方法和喷剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710054164.6A CN106667973A (zh) | 2017-01-22 | 2017-01-22 | 一种用于防雾霾损伤的组合物及其制备方法和喷剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106667973A true CN106667973A (zh) | 2017-05-17 |
Family
ID=58859325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710054164.6A Pending CN106667973A (zh) | 2017-01-22 | 2017-01-22 | 一种用于防雾霾损伤的组合物及其制备方法和喷剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106667973A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110960603A (zh) * | 2020-01-06 | 2020-04-07 | 泰州欣康生物技术有限公司 | 一种抗雾霾损伤组合物、其制备方法及使用方法 |
CN111265496A (zh) * | 2018-12-04 | 2020-06-12 | 高雄医学大学 | 抗雾霾组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2201964A2 (en) * | 2002-03-01 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Formoterol superfine formulation |
CN104095182A (zh) * | 2014-06-16 | 2014-10-15 | 李卫平 | 一种对雾霾引起的肺损伤具有保护作用的食品 |
CN105747047A (zh) * | 2016-03-22 | 2016-07-13 | 陈波 | 一种降低雾霾致肺损伤的防霾饮料及其制备方法 |
-
2017
- 2017-01-22 CN CN201710054164.6A patent/CN106667973A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2201964A2 (en) * | 2002-03-01 | 2010-06-30 | CHIESI FARMACEUTICI S.p.A. | Formoterol superfine formulation |
CN104095182A (zh) * | 2014-06-16 | 2014-10-15 | 李卫平 | 一种对雾霾引起的肺损伤具有保护作用的食品 |
CN105747047A (zh) * | 2016-03-22 | 2016-07-13 | 陈波 | 一种降低雾霾致肺损伤的防霾饮料及其制备方法 |
Non-Patent Citations (2)
Title |
---|
任永献,等: "《食物中毒的诊断和处理》", 31 March 2007, 中国科学技术出版社 * |
周艳丽,等: "阿魏酸拮抗大气PM2.5对大鼠肺的损伤作用", 《食品科学》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111265496A (zh) * | 2018-12-04 | 2020-06-12 | 高雄医学大学 | 抗雾霾组合物 |
CN110960603A (zh) * | 2020-01-06 | 2020-04-07 | 泰州欣康生物技术有限公司 | 一种抗雾霾损伤组合物、其制备方法及使用方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN207125951U (zh) | 一种医疗呼吸内科用喷药装置 | |
CN110353298A (zh) | 电子烟液 | |
CN208320411U (zh) | 一种物理生成高活性负氧离子装置 | |
CN106667973A (zh) | 一种用于防雾霾损伤的组合物及其制备方法和喷剂 | |
Kobayashi et al. | Diesel exhaust particulates induce nasal mucosal hyperresponsiveness to inhaled histamine aerosol | |
CN103861411A (zh) | 一种仿生空气净化方法及其专用仿生肺装置 | |
CN102626482B (zh) | 中药组合物在制备预防和改善肺部pm2.5沉积的药物中的应用 | |
CN107648980A (zh) | 一种环境净化剂及治理环境的方法 | |
CN113679085B (zh) | 一种电子雾化烟液及其制备方法 | |
CN102600412B (zh) | 中药组合物在制备预防和改善肺部pm2.5沉积的药物中的应用 | |
CN110179772A (zh) | 一种可供雾化吸入用的盐酸氨溴索制剂及其制备方法 | |
CN102626483B (zh) | 中药组合物在制备预防和改善肺部pm2.5沉积的药物中的应用 | |
CN110960603A (zh) | 一种抗雾霾损伤组合物、其制备方法及使用方法 | |
CN109998151A (zh) | 中链甘油三酯在改善和/或减少呼吸道刺激中的应用 | |
CN106692504B (zh) | 一种清咽止咳润肺防雾霾保健食品及其制备方法 | |
CN100531605C (zh) | 一种中式降焦减毒香烟及其制备方法 | |
CN209679849U (zh) | 一种天空节能自动捕霾装备 | |
CN208878166U (zh) | 一种移动式医用气溶胶高效吸附装置 | |
CN108854424A (zh) | 一种可净化空气的组合物 | |
CN205127617U (zh) | 一种以公共交通工具为载体的降低pm2.5雾化设备 | |
CN111838743B (zh) | 鼻烟及其制备方法 | |
CN113577173A (zh) | 用于治疗吸烟引起的咽部疾病的电子雾化液及制备方法 | |
CN107243024B (zh) | 一种双金连的药物组合物、一种双金连的雾化吸入用溶液及其制备方法和用途 | |
CN108993063A (zh) | 一种移动式医用气溶胶高效吸附装置 | |
CN110201507A (zh) | 一种基于酸性氨处理技术的烟气吸收工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170517 |